A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder
Running, not enrolling · Phase 2
Conditions studied: Major Depressive Disorder
In brief
Safety, Tolerability, pharmacokinetics and efficacy of a single administration of COMP360 in participants with recurrent Major Depressive Disorder.
Key facts
- Study ID
- NCT05733546
- Run by
- COMPASS Pathways
- People needed
- 102
- Starts
- 2023-01-30
- Expected to finish
- 2025-09-01
- Last updated by the study team
- 2025-08-19
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Kadima Neuropsychiatry Institute — La Jolla, California, United States
- Clinical Neuroscience Solutions Inc — Jacksonville, Florida, United States
- Sunstone Therapies — Rockville, Maryland, United States
- Elixia MA, LLC — Springfield, Massachusetts, United States
- Aims Trial — Plano, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.